-
Zhonghua Zhong Liu Za Zhi [Chinese... Mar 2010To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil... (Clinical Trial)
Clinical Trial Comparative Study
OBJECTIVE
To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer.
METHODS
The therapeutic efficacy of chemotherapy with either of the two regimens for 67 cases of naïve advanced gastric cancer was analyzed. Among them, 31 patients in the paclitaxel liposome-5-Fu group received paclitaxel liposome 175 mg/m(2) d1, CF 200 mg/m(2) d1, 5-Fu 2.6 g/m(2) civ. 46 hours, 21 days as one cycle, and 34 patients in the paclitaxel-5-Fu group received paclitaxel 175 mg/m(2) d1, CF 200 mg/m(2) d1, 5-Fu 2.6 g/m(2) civ. 46 hours, 21 days as one cycle.
RESULTS
The objective response rate was 54.8% in the paclitaxel liposome group and 44.1% in the paclitaxel group (P = 0.388). The median time to progression was 5.10 months vs. 5.20 months (P = 0.266) and the median survival time was 10.07 months vs. 8.97 months (P = 0.186). The most frequent side-effects were nausea, vomit and hematological toxicities. The rates of grade III-IV nausea and vomit were 16.1% and 50.0% (P = 0.038), muscle and joint pain were 9.7% and 29.4% (P = 0.047).
CONCLUSION
Both regimens are effective in the treatment of advanced gastric cancer. However, less adverse effects occur in the paclitaxel liposome group.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Liposomes; Male; Nausea; Paclitaxel; Remission Induction; Stomach Neoplasms; Survival Rate; Vomiting
PubMed: 20450596
DOI: No ID Found -
International Journal of Nanomedicine 2018In the present study, the tumor-specific, pH-responsive peptide HK(R)-modified, theranostic liposome-containing paclitaxel (PTX) and superparamagnetic iron oxide...
BACKGROUND
In the present study, the tumor-specific, pH-responsive peptide HK(R)-modified, theranostic liposome-containing paclitaxel (PTX) and superparamagnetic iron oxide nanoparticles (SPIO NPs), PTX/SPIO-SSL-HK(R), was prepared by using HK(R) as the targeting ligand, SPIO NPs as the magnetic resonance imaging (MRI) agent, PTX as antitumor drug.
METHODS
The PTX/SPIO-SSL-HK(R) was prepared by a thin film hydration method. The characteristics of PTX/SPIO-SSL-HK(R) were evaluated. The targeting effect, MRI, and antitumor activity of PTX/SPIO-SSL-HK(R) were investigated detail in vitro and in vivo in human breast carcinoma MDA-MB-231 cell models.
RESULTS
Our results of in vitro flow cytometry, in vivo imaging, and in vivo MR imaging confirmed the pH-responsive characteristic of HK(R) in MDA-MB-231 cell line in vitro and in vivo. The results of in vivo MRI and in vivo antitumor activity confirmed the theranostic effect of PTX/SPIO-SSL-HK(R) in MDA-MB-231 tumor-bearing model.
CONCLUSION
Considering all our in vitro and in vivo results, we conclude that we developed targeting modified theranostic liposome which could achieve both role of antitumor and MRI.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Liberation; Female; Ferric Compounds; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Liposomes; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptides; Theranostic Nanomedicine; Tissue Distribution
PubMed: 29559778
DOI: 10.2147/IJN.S157082 -
Future Oncology (London, England) May 2019To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer...
To compare the performance of first-line paclitaxel liposome + oxaliplatin and SOX (tegafur/gimeracil/oteracil + oxaliplatin) in advanced gastric cancer patients. Stage IIb-IV gastric cancer patients underwent either first-line paclitaxel liposome + oxaliplatin (n = 52) or SOX (n = 69) between 2010-2013, and followed up until 2015 or death. Both groups had similar objective response rate (p = 0.48) and disease control rate (p = 0.992) after two chemotherapy cycles, median progression-free survival (p = 0.495) and median overall survival (p = 0.208). Liposome group had significantly lower rate of grade I-II platelet decline and liver function damage (p = 0.04 and 0.019). Multivariate COX regression identified pre-treatment neutrophil-to-lymphocyte ratio as an independent prognostic factor. First-line paclitaxel liposome + oxaliplatin has comparable efficacy, but causes reduced adverse reactions in advanced gastric cancer as compared with SOX.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Female; Follow-Up Studies; Humans; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Stomach Neoplasms; Treatment Outcome
PubMed: 31038363
DOI: 10.2217/fon-2018-0439 -
Journal of Liposome Research Mar 2020Multidrug resistance (MDR) is the largest obstacle to the success of chemotherapy. The development of innovative strategies and safe sensitizers is required to overcome...
Multidrug resistance (MDR) is the largest obstacle to the success of chemotherapy. The development of innovative strategies and safe sensitizers is required to overcome MDR. Paclitaxel (PTX) is a widely used chemotherapeutic drug, the application of which has been learn to understand MDR. However, the application and use are severely restricted because of this MDR. Cyclodextrins (CDs) of many carriers, additionally have shown anti-cancer capability in MDR cancer cells. In this study, novel paclitaxel/hydroxypropyl-β-cyclodextrin complex-loaded liposomes (PTXCDL) have been developed in an attempt to overcome MDR in a PTX-resistant human lung adenocarcinoma (A549/T) cell line. The application of PTXCDL exhibited pH-sensitive PTX release, potent cytotoxicity, and enhanced intracellular accumulation. In comparison to , PTXCDL also show a stronger inhibition of tumor growth. In comparison, these findings suggest that the PTXCDL provide a novel strategy for effective therapy of resistant cancers by overcoming the drug resistance.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Cyclodextrins; Drug Compounding; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Liposomes; Nanoparticles; Paclitaxel; Treatment Outcome
PubMed: 30741058
DOI: 10.1080/08982104.2019.1579838 -
Biomaterials Jan 2012In this study, we report an angiopep-2 modified cationic liposome (ANG-CLP) for the efficient co-delivery of a therapeutic gene encoding the human tumour necrosis...
In this study, we report an angiopep-2 modified cationic liposome (ANG-CLP) for the efficient co-delivery of a therapeutic gene encoding the human tumour necrosis factor-related apoptosis-inducing ligand (pEGFP-hTRAIL) and paclitaxel (PTX) to glioma. The dual targeting co-delivery system (ANG-CLP/PTX/pEGFP-hTRAIL) improved uptake and gene expression not only in U87 MG cells and BCECs, but also in the glioma bed and infiltrating margin of intracranial U87 MG glioma-bearing models. The system selectively induces apoptosis in U87 MG cells while reducing toxicity to BCECs. The results of the pharmacodynamics studies showed that the apoptosis of glioma cells in in vitro BBB models and in U87 MG glioma-bearing mice induced by ANG-CLP/PTX/pEGFP-hTRAIL was more apparent and widespread than that induced by single medication systems and unmodified co-delivery system. More importantly, the median survival time of brain tumour-bearing mice treated with ANG-CLP/PTX/pEGFP-hTRAIL was 69.5 days, significantly longer than that of other groups, even longer than the commercial temozolomide group (47 days). Therefore, the dual targeting co-delivery system is a promising drug delivery strategy against glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Glioma; Humans; Liposomes; Mice; Mice, Inbred BALB C; Microscopy, Atomic Force; Paclitaxel; Peptides; TNF-Related Apoptosis-Inducing Ligand
PubMed: 22048008
DOI: 10.1016/j.biomaterials.2011.10.035 -
Biomaterials Feb 2018To prevent bone metastasis, we developed polyethylene glycol (PEG)-conjugated aspartic acid (Asp)-modified liposomes (PEG-Asp-Lipo) as a bone-targeting carrier of...
To prevent bone metastasis, we developed polyethylene glycol (PEG)-conjugated aspartic acid (Asp)-modified liposomes (PEG-Asp-Lipo) as a bone-targeting carrier of paclitaxel (PTX) by using Asp-modified 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE-Asp). The affinity of Asp-modified liposomes to hydroxyapatite increased as the concentration of DPPE-Asp increased. The bone accumulation of [H]-labeled PEG(2)-Asp(33)-Lipo was approximately 24.6% 360 min after intravenous injection in mice, in contrast to 5.4% and 6.7% of [H]-labeled normal Lipo and PEG(2)-Lipo, respectively. Similarly, [C]-labeled PTX encapsulated into PEG(2)-Asp(33)-Lipo predominantly accumulated in the bone. Furthermore, using an in situ imaging experiment, we observed that near-infrared fluorescence-labeled PEG(2)-Asp(33)-Lipo selectively accumulated in the bone near the joint after intravenous injection in mice. We also found that FITC-labeled PEG(2)-Asp(33)-Lipo predominantly accumulated on eroded and quiescent bone surfaces. In a bone metastatic tumor mouse model, in which B16-BL6/Luc cells were injected into the left ventricle of female C57BL/6 mice, metastatic bone tumor growth was significantly inhibited by an intravenous injection of PEG(2)-Asp(33)-liposomal PTX. In contrast, PEGylated liposomal PTX hardly affected the growth of metastatic bone tumors. These findings indicate that PEG(2)-Asp(33)-Lipo is a promising bone-targeting carrier for the delivery of PTX and treatment of bone metastasis.
Topics: Animals; Apoptosis; Aspartic Acid; Bone Neoplasms; Bone and Bones; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Female; Flow Cytometry; Fluorescent Dyes; Liposomes; Male; Mice, Inbred C57BL; Osteoclasts; Paclitaxel; Polyethylene Glycols; Time Factors; Tissue Distribution; Tritium
PubMed: 29120820
DOI: 10.1016/j.biomaterials.2017.10.053 -
Clinical Cancer Research : An Official... Oct 2001The present studies were undertaken to evaluate the pulmonary pharmacokinetics and therapeutic efficacy of paclitaxel (PTX) administered by aerosol. PTX was encapsulated...
The present studies were undertaken to evaluate the pulmonary pharmacokinetics and therapeutic efficacy of paclitaxel (PTX) administered by aerosol. PTX was encapsulated into dilauroylphosphatidylcholine liposomal formulations (PTX-DLPC). The deposition and clearance of PTX-DLPC in the lungs administered by aerosol or i.v. at comparative doses was performed, and PTX was quantitatively determined in tissue extracts by high-performance liquid chromatography analysis. The murine renal carcinoma (Renca) pulmonary metastases model was used to determine the therapeutic effect of drug formulation administered by aerosol. PTX-DLPC aerosols were generated with the Aero-Mist jet nebulizer (cis-USA). The most effective schedule of treatment was when mice inhaled the drug for 30 min 3 days per week. There was a significant reduction of the lung weights and reduced number of visible tumor foci on the lung surfaces of mice treated with PTX aerosol (P < 0.004 and P < 0.01, respectively) compared with control groups. Inhalation of PTX-DLPC also led to prolonged survival in mice inoculated with Renca cells. The results of the present studies demonstrate the therapeutic potential of aerosol technology for lung cancer treatment.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Renal Cell; Cricetinae; Injections, Intravenous; Kidney Neoplasms; Liposomes; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Organ Size; Paclitaxel; Survival Rate; Time Factors; Tumor Cells, Cultured
PubMed: 11595722
DOI: No ID Found -
Journal of Controlled Release :... Jul 2007A sterically stabilized paclitaxel-loaded liposome tailored to target human breast cancer cells was developed, thereby promoting the efficiency of intracellular delivery... (Comparative Study)
Comparative Study
A sterically stabilized paclitaxel-loaded liposome tailored to target human breast cancer cells was developed, thereby promoting the efficiency of intracellular delivery of paclitaxel through receptor-mediated endocytosis. Results indicated that the targeting moiety (thiolated Herceptin) was successfully coupled to the distal reactive maleimide terminus of the poly (ethylene glycol)-phospholipid conjugate as well as being incorporated in the liposomal bilayers. The particle size of the PEGylated immunoliposome was maintained at about 200 nm. Confocal microscopy studies showed that the PEGylated immunoliposome was uptaken into the interior of the tumor cell through the receptor-mediated endocytosis pathway. The PEGylated immunoliposome showed substantially higher cellular uptake than the PEGylated liposome in cancer cells (BT-474 and SK-BR-3) over-expressing human epidermal growth factor receptor 2 (HER2) at 37 degrees C, while no difference was found in low HER2 expressing cells (MDA-MB-231) nor at low temperature (4 degrees C). Pharmacokinetics of paclitaxel in the PEGylated immunoliposome was compared with that in Taxol and in the PEGylated liposome in rats. The circulating time of paclitaxel in the PEGylated immunoliposome was prolonged compared to Taxol while slightly shortened than that in the PEGylated liposome. Therefore, the paclitaxel-loaded PEGylated immunoliposome using Herceptin could serve as a promising model for future tumor specific cancer therapy of HER2 over-expressing breast cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Breast Neoplasms; Cell Line, Tumor; Female; Half-Life; Humans; Immunoconjugates; Liposomes; Male; Metabolic Clearance Rate; Paclitaxel; Particle Size; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Trastuzumab
PubMed: 17586082
DOI: 10.1016/j.jconrel.2007.05.011 -
Artificial Cells, Nanomedicine, and... 2016In the present paper, paclitaxel (PTX)-loaded stealth liposomes were prepared with thin film hydration technique in order to prolong the time of circulation.
AIM
In the present paper, paclitaxel (PTX)-loaded stealth liposomes were prepared with thin film hydration technique in order to prolong the time of circulation.
METHOD
The liposomes' characterization, in vitro release, pharmacokinetics, and biodistribution profile of the drug were investigated.
RESULTS
Microscope showed that the liposomes were spherical in shape with a smooth surface and the size was uniform and appropriate for administration via intravenous injection. The encapsulation efficiency was 91.1 ± 4.3%, and the mean diameter was 82.2 ± 7.6 nm from three batches. The results of in vivo studies indicated that PTX-loaded stealth liposomes show favorable pharmacokinetics and biodistribution compared to the free drug. In comparison with free PTX, the AUC0-t of PTX liposomes and stealth liposomes increased 1.91- and 3.39-fold, respectively. The stealth liposomes were long-circulating showing a half-life time of 34.2 h against 13.7 h for the conventional ones.
CONCLUSIONS
These results suggest that stealth liposomes would serve as a potent PTX delivery vehicle for the future cancer chemotherapy and represent a suitable platform for the development of targeted liposomal PTX systems.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Carcinoma; Cell Line, Tumor; Cholesterol; Drug Compounding; Drug Liberation; Half-Life; Humans; Injections, Intravenous; Liposomes; Liver; Lung Neoplasms; Mice; Paclitaxel; Phosphatidylcholines; Phosphatidylethanolamines; Polyethylene Glycols; Rats, Sprague-Dawley; Spleen; Tissue Distribution; Xenograft Model Antitumor Assays
PubMed: 25162671
DOI: 10.3109/21691401.2014.951722 -
The Journal of International Medical... Sep 2023To compare the efficacy of paclitaxel liposomes combined with carboplatin and paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer and assess... (Observational Study)
Observational Study
OBJECTIVE
To compare the efficacy of paclitaxel liposomes combined with carboplatin and paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer and assess their effects on serum human epididymis protein 4 (HE4), CA125, CA199, matrix metalloproteinase-2 (MMP2), MMP-7, and MMP-9 levels.
METHODS
In this observational study, 102 patients with advanced ovarian cancer were assigned to receive paclitaxel liposomes combined with carboplatin (Group A) or paclitaxel combined with carboplatin (Group B). Clinical efficacy; serum HE4, CA125, CA199, MMP-2, MMP-7, and MMP-9 levels; and the occurrence of adverse reactions were compared between the groups.
RESULTS
The overall response rate was significantly higher in Group A than in Group B. After chemotherapy, serum HE4, CA125, CA199, MMP-2, MMP-7, and MMP-9 levels were lower in Group A than in Group B. The incidence of myalgia, dyspnea, nausea and vomiting, facial flushing, peripheral neuropathy, and skin rash was lower in Group A than in Group B.
CONCLUSION
Paclitaxel liposomes combined with carboplatin displayed better efficacy in the treatment of advanced ovarian cancer than paclitaxel combined with carboplatin, which might be attributable to reductions in serum marker levels and the occurrence of adverse events.
Topics: Female; Humans; Matrix Metalloproteinase 2; Carboplatin; Liposomes; Matrix Metalloproteinase 7; Matrix Metalloproteinase 9; Paclitaxel; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms
PubMed: 37756606
DOI: 10.1177/03000605231200267